EGFR and non-small cell lung carcinoma: Patients with EGFR-mutated NSCLC are also commonly comorbid with other mutations, and for patients with EGFR-mutated NSCLC, the modulatory effect of EGFR mutations on the efficacy of immunotherapy is also likely to be affected by the inclusion of other mutations (25, 26).